U.S. Physical Therapy (USPH) Stock Looks Above Fair Value Despite Its 13% Five Year Fall

U.S. Physical Therapy has delivered a mixed share price story, with modest gains over the past year alongside a longer term decline, which puts fresh attention on what investors are really paying for its sales. The question now is whether the current US$85.83 price tag lines up with the revenue the business produces.

• Over the last 5 years the stock has declined 12.9%, which puts the spotlight on whether the existing sales base can support a sustained recovery in valuation.
• The company earns its money one patient visit at a time, so future top-line potential depends heavily on clinic productivity, reimbursement trends and how effectively it can grow visit volumes without eroding profitability.
• The analysts covering U.S. Physical Therapy have run their own numbers. See what analysts think U.S. Physical Therapy's shares could be worth.

For investors, the debate is whether U.S. Physical Therapy's current share price is appropriately anchored to its sales performance and revenue outlook.

As you weigh whether U.S. Physical Therapy's current price fairly reflects its sales, it can help to compare it against a wider set of companies screened for 33 high quality undervalued stocks.

Does U.S. Physical Therapy Look Pricey on Sales?

P/S fits U.S. Physical Therapy quite well because this is a healthcare services group where investors often focus on how much revenue the current market value is asking them to pay for. On that lens, the stock trades on a P/S of about 1.6x, slightly above both the healthcare industry average of roughly 1.4x and the peer group around 1.4x. That points to investors paying a small premium for each dollar of the clinic network's revenue compared with similar businesses.

The Fair Ratio model, which factors in U.S. Physical Therapy's growth profile, margins, size and risk, points to a lower P/S than the market is currently assigning. That gap suggests the shares screen as overvalued on this revenue based yardstick, so you would need to be comfortable that the quality and durability of its patient visit stream justify paying more per dollar of sales than the framework implies. Explore the numbers behind U.S. Physical Therapy's P/S valuation.

The U.S. Physical Therapy Narrative: What Would Justify Today's Price?

Narratives for U.S. Physical Therapy pick up where the P/S puzzle leaves off by spelling out what kind of future growth, profitability and earnings path would need to show up for the stock to be worth materially more or materially less than today’s price on Simply Wall St's Community page. Each scenario links its number to a clear view on how revenue trends, margins and business risks might evolve, which you can test against new information over time.

One of the top community narratives on U.S. Physical Therapy: 12% undervalued

"The current valuation implies the market discounts the durability of record visit volumes and higher revenue per visit…"

Discover why this Narrative puts U.S. Physical Therapy at 12% undervalued.

Before you act on U.S. Physical Therapy’s valuation, there is one more piece to check

Price tells you what the market thinks of U.S. Physical Therapy, but the people setting priorities, taking capital allocation decisions and how they are rewarded can pull that story in a very different direction. See who runs U.S. Physical Therapy and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com